<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd" xmlns:googleplay="http://www.google.com/schemas/play-podcasts/1.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:media="http://search.yahoo.com/mrss/" xmlns:content="http://purl.org/rss/1.0/modules/content/">
  <channel>
    <atom:link href="https://feeds.megaphone.fm/WRBM4839853338" rel="self" type="application/rss+xml"/>
    <title>The Biopharma Pod</title>
    <link>https://www.biopharma-reporter.com</link>
    <language>en</language>
    <copyright>℗ &amp; ©  William Reed Ltd</copyright>
    <description>Brought to you by the team behind BioPharma-Reporter.com</description>
    <image>
      <url>https://megaphone.imgix.net/podcasts/596ae896-cdbc-11ea-a46d-a739d4315821/image/80306d939e9fe8d625d591518328ee29.jpg?ixlib=rails-4.3.1&amp;max-w=3000&amp;max-h=3000&amp;fit=crop&amp;auto=format,compress</url>
      <title>The Biopharma Pod</title>
      <link>https://www.biopharma-reporter.com</link>
    </image>
    <itunes:explicit>no</itunes:explicit>
    <itunes:type>episodic</itunes:type>
    <itunes:subtitle></itunes:subtitle>
    <itunes:author>William Reed Ltd</itunes:author>
    <itunes:summary>Brought to you by the team behind BioPharma-Reporter.com</itunes:summary>
    <content:encoded>
      <![CDATA[<p>Brought to you by the team behind BioPharma-Reporter.com</p>]]>
    </content:encoded>
    <itunes:owner>
      <itunes:name>William Reed Ltd</itunes:name>
      <itunes:email>podcasts@wrbm.com</itunes:email>
    </itunes:owner>
    <itunes:image href="https://megaphone.imgix.net/podcasts/596ae896-cdbc-11ea-a46d-a739d4315821/image/80306d939e9fe8d625d591518328ee29.jpg?ixlib=rails-4.3.1&amp;max-w=3000&amp;max-h=3000&amp;fit=crop&amp;auto=format,compress"/>
    <itunes:category text="News">
      <itunes:category text="Business News"/>
    </itunes:category>
    <itunes:category text="Science">
    </itunes:category>
    <item>
      <title>Podcast: The British start-up taking psychedelic therapy mainstream</title>
      <description>In our first podcast interview of 2023, BioPharma Reporter spoke with Dr Sarah Bateup, therapy lead at Clerkenwell Health, about the potential of psychedelic medicine and her work within the psychedelic therapy training space.</description>
      <pubDate>Mon, 16 Oct 2023 13:28:00 -0000</pubDate>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:author>William Reed Ltd</itunes:author>
      <itunes:subtitle/>
      <itunes:summary>In our first podcast interview of 2023, BioPharma Reporter spoke with Dr Sarah Bateup, therapy lead at Clerkenwell Health, about the potential of psychedelic medicine and her work within the psychedelic therapy training space.</itunes:summary>
      <content:encoded>
        <![CDATA[In our first podcast interview of 2023, BioPharma Reporter spoke with Dr Sarah Bateup, therapy lead at Clerkenwell Health, about the potential of psychedelic medicine and her work within the psychedelic therapy training space. ]]>
      </content:encoded>
      <itunes:duration>1713</itunes:duration>
      <guid isPermaLink="false"><![CDATA[801de9a4-6c27-11ee-8f9c-33f03708ef9b]]></guid>
      <enclosure url="https://traffic.megaphone.fm/WRBM7919263471.mp3?updated=1697467107" length="0" type="audio/mpeg"/>
    </item>
    <item>
      <title>What kind of consistency can industry expect from the FDA post pandemic? </title>
      <description>How the US Food and Drug Administration (FDA) exercises flexibility has been an important and emerging issue for the past several years.</description>
      <pubDate>Thu, 22 Jul 2021 08:37:00 -0000</pubDate>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:author>William Reed Ltd</itunes:author>
      <itunes:subtitle/>
      <itunes:summary>How the US Food and Drug Administration (FDA) exercises flexibility has been an important and emerging issue for the past several years.</itunes:summary>
      <content:encoded>
        <![CDATA[How the US Food and Drug Administration (FDA) exercises flexibility has been an important and emerging issue for the past several years.]]>
      </content:encoded>
      <itunes:duration>905</itunes:duration>
      <guid isPermaLink="false"><![CDATA[c538ac06-eacc-11eb-ba95-43b18ec06fa0]]></guid>
      <enclosure url="https://traffic.megaphone.fm/WRBM4847833408.mp3?updated=1626946099" length="0" type="audio/mpeg"/>
    </item>
    <item>
      <title>Chicago emerging as a life science and biopharma hub</title>
      <description>Many turn to Boston and North Carolina’s Research Triangle to set up life science companies, but Chicago is now also fast becoming a draw in this respect. The city is emerging as a life science and biopharma hub and seems poised for even further growth, in CGT in particular.</description>
      <pubDate>Mon, 17 May 2021 13:16:00 -0000</pubDate>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:author>William Reed Ltd</itunes:author>
      <itunes:subtitle/>
      <itunes:summary>Many turn to Boston and North Carolina’s Research Triangle to set up life science companies, but Chicago is now also fast becoming a draw in this respect. The city is emerging as a life science and biopharma hub and seems poised for even further growth, in CGT in particular.</itunes:summary>
      <content:encoded>
        <![CDATA[Many turn to Boston and North Carolina’s Research Triangle to set up life science companies, but Chicago is now also fast becoming a draw in this respect. The city is emerging as a life science and biopharma hub and seems poised for even further growth, in CGT in particular.  ]]>
      </content:encoded>
      <itunes:duration>896</itunes:duration>
      <guid isPermaLink="false"><![CDATA[81cc638c-b713-11eb-b539-13194332130a]]></guid>
      <enclosure url="https://traffic.megaphone.fm/WRBM6028736186.mp3" length="0" type="audio/mpeg"/>
    </item>
    <item>
      <title>Will Biden backed bills boost biosimilars uptake in the US?</title>
      <description>Today we are launching a new series called The BioPharma Pod. Kicking off these broadcasts is the hot topic of biosimilars.</description>
      <pubDate>Fri, 07 May 2021 08:58:00 -0000</pubDate>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:author>William Reed Ltd</itunes:author>
      <itunes:subtitle/>
      <itunes:summary>Today we are launching a new series called The BioPharma Pod. Kicking off these broadcasts is the hot topic of biosimilars.</itunes:summary>
      <content:encoded>
        <![CDATA[Today we are launching a new series called The BioPharma Pod. Kicking off these broadcasts is the hot topic of biosimilars.]]>
      </content:encoded>
      <itunes:duration>528</itunes:duration>
      <guid isPermaLink="false"><![CDATA[79fa6e94-af19-11eb-b1aa-bbf73d208a49]]></guid>
      <enclosure url="https://traffic.megaphone.fm/WRBM4976995770.mp3?updated=1620385270" length="0" type="audio/mpeg"/>
    </item>
    <item>
      <title>Bioproduction bottlenecks increasing due to staff shortages, says report</title>
      <description>A shortage in expertise is causing bottlenecks in the biomanufacturing space with around half of drugmakers struggling to fill processing positions, an industry report finds.</description>
      <pubDate>Tue, 15 Aug 2017 23:00:00 -0000</pubDate>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:author>William Reed Ltd</itunes:author>
      <itunes:subtitle/>
      <itunes:summary>A shortage in expertise is causing bottlenecks in the biomanufacturing space with around half of drugmakers struggling to fill processing positions, an industry report finds.</itunes:summary>
      <content:encoded>
        <![CDATA[A shortage in expertise is causing bottlenecks in the biomanufacturing space with around half of drugmakers struggling to fill processing positions, an industry report finds.]]>
      </content:encoded>
      <itunes:duration>241</itunes:duration>
      <guid isPermaLink="false"><![CDATA[ae24230c-e1f8-11ea-a911-23fce7298071]]></guid>
      <enclosure url="https://traffic.megaphone.fm/WRBM9541058837.mp3" length="0" type="audio/mpeg"/>
    </item>
    <item>
      <title>'The sexiness of the ADC world' - CMOs talk antibody-drug hybrids at CPhI</title>
      <description>Piramal’s COO Vijay Shah described antibody-drug conjugates (ADCs) as “a concept whose time has come” at the CPhI annual report press conference and recent investors in the technology echo his words.</description>
      <pubDate>Wed, 30 Oct 2013 00:00:00 -0000</pubDate>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:author>William Reed Ltd</itunes:author>
      <itunes:subtitle/>
      <itunes:summary>Piramal’s COO Vijay Shah described antibody-drug conjugates (ADCs) as “a concept whose time has come” at the CPhI annual report press conference and recent investors in the technology echo his words.</itunes:summary>
      <content:encoded>
        <![CDATA[Piramal’s COO Vijay Shah described antibody-drug conjugates (ADCs) as “a concept whose time has come” at the CPhI annual report press conference and recent investors in the technology echo his words.]]>
      </content:encoded>
      <itunes:duration>342</itunes:duration>
      <guid isPermaLink="false"><![CDATA[8adefc5a-e1f8-11ea-9132-e7278448b0e9]]></guid>
      <enclosure url="https://traffic.megaphone.fm/WRBM6589347918.mp3" length="0" type="audio/mpeg"/>
    </item>
    <item>
      <title>Better single-use cross flow techs still needed says GE Healthcare</title>
      <description>The biopharmaceutical manufacturing sector needs better cross flow filtration technologies according to GE Healthcare, which says that advances in bioreactor systems have not been matched downstream.</description>
      <pubDate>Tue, 15 Oct 2013 23:00:00 -0000</pubDate>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:author>William Reed Ltd</itunes:author>
      <itunes:subtitle/>
      <itunes:summary>The biopharmaceutical manufacturing sector needs better cross flow filtration technologies according to GE Healthcare, which says that advances in bioreactor systems have not been matched downstream.</itunes:summary>
      <content:encoded>
        <![CDATA[The biopharmaceutical manufacturing sector needs better cross flow filtration technologies according to GE Healthcare, which says that advances in bioreactor systems have not been matched downstream.]]>
      </content:encoded>
      <itunes:duration>185</itunes:duration>
      <guid isPermaLink="false"><![CDATA[9a809a06-e1f8-11ea-b7ac-33905c2d0722]]></guid>
      <enclosure url="https://traffic.megaphone.fm/WRBM1513823290.mp3" length="0" type="audio/mpeg"/>
    </item>
    <item>
      <title>Immunocore CEO: 3rd Big Pharma Eying Unique Cancer Targeting Tech</title>
      <description>Immunocore is looking for more licensees for its cancer targeting technology following recent discovery and development deals with GSK and Genentech.</description>
      <pubDate>Tue, 16 Jul 2013 23:00:00 -0000</pubDate>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:author>William Reed Ltd</itunes:author>
      <itunes:subtitle/>
      <itunes:summary>Immunocore is looking for more licensees for its cancer targeting technology following recent discovery and development deals with GSK and Genentech.</itunes:summary>
      <content:encoded>
        <![CDATA[Immunocore is looking for more licensees for its cancer targeting technology following recent discovery and development deals with GSK and Genentech.]]>
      </content:encoded>
      <itunes:duration>310</itunes:duration>
      <guid isPermaLink="false"><![CDATA[862d7614-e1f8-11ea-9132-9790c008ab39]]></guid>
      <enclosure url="https://traffic.megaphone.fm/WRBM4155686509.mp3" length="0" type="audio/mpeg"/>
    </item>
    <item>
      <title>Customers to Save up to 65% as ASI and Chromatan Pen Single-Use Deal</title>
      <description>ASI has teamed up with Chromatan in order to deliver single-use and column-free capture purification services which could save clients 65% in chromatography costs in clinical manufacturing.</description>
      <pubDate>Mon, 29 Apr 2013 23:00:00 -0000</pubDate>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:author>William Reed Ltd</itunes:author>
      <itunes:subtitle/>
      <itunes:summary>ASI has teamed up with Chromatan in order to deliver single-use and column-free capture purification services which could save clients 65% in chromatography costs in clinical manufacturing.</itunes:summary>
      <content:encoded>
        <![CDATA[ASI has teamed up with Chromatan in order to deliver single-use and column-free capture purification services which could save clients 65% in chromatography costs in clinical manufacturing.]]>
      </content:encoded>
      <itunes:duration>308</itunes:duration>
      <guid isPermaLink="false"><![CDATA[9411ee04-e1f8-11ea-b707-d7af133cd6b8]]></guid>
      <enclosure url="https://traffic.megaphone.fm/WRBM1669958201.mp3" length="0" type="audio/mpeg"/>
    </item>
    <item>
      <title>ATMI: Single Use Bioreactors on the Up, but US Tails Europe</title>
      <description>New innovations in single-use bioprocessing systems are being picked up quicker in Europe than in the US, according to ATMI.</description>
      <pubDate>Wed, 20 Feb 2013 00:00:00 -0000</pubDate>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:author>William Reed Ltd</itunes:author>
      <itunes:subtitle/>
      <itunes:summary>New innovations in single-use bioprocessing systems are being picked up quicker in Europe than in the US, according to ATMI.</itunes:summary>
      <content:encoded>
        <![CDATA[New innovations in single-use bioprocessing systems are being picked up quicker in Europe than in the US, according to ATMI.]]>
      </content:encoded>
      <itunes:duration>283</itunes:duration>
      <guid isPermaLink="false"><![CDATA[a246a7e4-e1f8-11ea-9c6c-c74bb0956f2e]]></guid>
      <enclosure url="https://traffic.megaphone.fm/WRBM1954760257.mp3" length="0" type="audio/mpeg"/>
    </item>
    <item>
      <title>The single-use age has dawned, says ThermoFisher</title>
      <description>Developments in single-use technology signals the end for clean-in-place biomanufacturing methods, according to ThermoFisher’s Bill Whitford.</description>
      <pubDate>Sun, 20 May 2012 23:00:00 -0000</pubDate>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:author>William Reed Ltd</itunes:author>
      <itunes:subtitle/>
      <itunes:summary>Developments in single-use technology signals the end for clean-in-place biomanufacturing methods, according to ThermoFisher’s Bill Whitford.</itunes:summary>
      <content:encoded>
        <![CDATA[Developments in single-use technology signals the end for clean-in-place biomanufacturing methods, according to ThermoFisher’s Bill Whitford.]]>
      </content:encoded>
      <itunes:duration>316</itunes:duration>
      <guid isPermaLink="false"><![CDATA[a7707510-e1f8-11ea-ba4e-b750e0494278]]></guid>
      <enclosure url="https://traffic.megaphone.fm/WRBM5542130966.mp3" length="0" type="audio/mpeg"/>
    </item>
    <item>
      <title>European CMO market will double in just 6 years, says Frost &amp; Sullivan</title>
      <description>The European CMO sector is set to double in the next six years and will hit revenues of up to $20.75bn, according to Frost &amp; Sullivan’s Aiswariya Chidambaram.</description>
      <pubDate>Thu, 15 Mar 2012 00:00:00 -0000</pubDate>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:author>William Reed Ltd</itunes:author>
      <itunes:subtitle/>
      <itunes:summary>The European CMO sector is set to double in the next six years and will hit revenues of up to $20.75bn, according to Frost &amp; Sullivan’s Aiswariya Chidambaram.</itunes:summary>
      <content:encoded>
        <![CDATA[The European CMO sector is set to double in the next six years and will hit revenues of up to $20.75bn, according to Frost &amp; Sullivan’s Aiswariya Chidambaram.]]>
      </content:encoded>
      <itunes:duration>349</itunes:duration>
      <guid isPermaLink="false"><![CDATA[8995bc30-e1f8-11ea-9132-9fd8b2805ed7]]></guid>
      <enclosure url="https://traffic.megaphone.fm/WRBM3962317942.mp3" length="0" type="audio/mpeg"/>
    </item>
    <item>
      <title>Acuros in talks with Big Pharma over water-powered delivery pump</title>
      <description>Acuros is seeking development partnerships with Big Pharma over its recently launched water-powered drug delivery pump.</description>
      <pubDate>Tue, 13 Mar 2012 00:00:00 -0000</pubDate>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:author>William Reed Ltd</itunes:author>
      <itunes:subtitle/>
      <itunes:summary>Acuros is seeking development partnerships with Big Pharma over its recently launched water-powered drug delivery pump.</itunes:summary>
      <content:encoded>
        <![CDATA[Acuros is seeking development partnerships with Big Pharma over its recently launched water-powered drug delivery pump.]]>
      </content:encoded>
      <itunes:duration>354</itunes:duration>
      <guid isPermaLink="false"><![CDATA[99465482-e1f8-11ea-9c6c-938010f68db0]]></guid>
      <enclosure url="https://traffic.megaphone.fm/WRBM3530809344.mp3" length="0" type="audio/mpeg"/>
    </item>
    <item>
      <title>Unilife launches Autoinfuser range publically</title>
      <description>Unilife is expanding its large dose delivery platform in a bid to meet a “growing industry need” for at-home drug administration in bigger scale.</description>
      <pubDate>Thu, 23 Feb 2012 00:00:00 -0000</pubDate>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:author>William Reed Ltd</itunes:author>
      <itunes:subtitle/>
      <itunes:summary>Unilife is expanding its large dose delivery platform in a bid to meet a “growing industry need” for at-home drug administration in bigger scale.</itunes:summary>
      <content:encoded>
        <![CDATA[Unilife is expanding its large dose delivery platform in a bid to meet a “growing industry need” for at-home drug administration in bigger scale.]]>
      </content:encoded>
      <itunes:duration>265</itunes:duration>
      <guid isPermaLink="false"><![CDATA[a8bd3ef8-e1f8-11ea-a61e-bb51202e8997]]></guid>
      <enclosure url="https://traffic.megaphone.fm/WRBM4603810304.mp3" length="0" type="audio/mpeg"/>
    </item>
    <item>
      <title>EMD Millipore talks integration: of processes; and with owner Merck KGaA</title>
      <description>The biomanufacturing industry needs to adopt an integrated approach to upstream and downstream processing to boost efficiency and productivity according to EMD Millipore.</description>
      <pubDate>Tue, 05 Apr 2011 23:00:00 -0000</pubDate>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:author>William Reed Ltd</itunes:author>
      <itunes:subtitle/>
      <itunes:summary>The biomanufacturing industry needs to adopt an integrated approach to upstream and downstream processing to boost efficiency and productivity according to EMD Millipore.</itunes:summary>
      <content:encoded>
        <![CDATA[The biomanufacturing industry needs to adopt an integrated approach to upstream and downstream processing to boost efficiency and productivity according to EMD Millipore.]]>
      </content:encoded>
      <itunes:duration>244</itunes:duration>
      <guid isPermaLink="false"><![CDATA[9fa065ac-e1f8-11ea-80c5-8b3cc2438dc3]]></guid>
      <enclosure url="https://traffic.megaphone.fm/WRBM8916910437.mp3" length="0" type="audio/mpeg"/>
    </item>
    <item>
      <title>OctoPlus, Glycotope, Merck KGaA and SCM Pharma on BioPh 2009</title>
      <description>How successful was the BioPh conference in Madrid? in-PharmaTechnologist asked key players attending the inaugural event.</description>
      <pubDate>Thu, 29 Oct 2009 00:00:00 -0000</pubDate>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:author>William Reed Ltd</itunes:author>
      <itunes:subtitle/>
      <itunes:summary>How successful was the BioPh conference in Madrid? in-PharmaTechnologist asked key players attending the inaugural event.</itunes:summary>
      <content:encoded>
        <![CDATA[How successful was the BioPh conference in Madrid? in-PharmaTechnologist asked key players attending the inaugural event.]]>
      </content:encoded>
      <itunes:duration>255</itunes:duration>
      <guid isPermaLink="false"><![CDATA[83507bd0-e1f8-11ea-b81f-73630e484c79]]></guid>
      <enclosure url="https://traffic.megaphone.fm/WRBM7118012384.mp3" length="0" type="audio/mpeg"/>
    </item>
    <item>
      <title>Gene therapy to drive viral and biologics market, says SAFC</title>
      <description>SAFC Pharma has added extra viral and biologics capacity at its California plant in a $12m project that allows it to take projects from the lab to commercial scale.</description>
      <pubDate>Tue, 13 Oct 2009 23:00:00 -0000</pubDate>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:author>William Reed Ltd</itunes:author>
      <itunes:subtitle/>
      <itunes:summary>SAFC Pharma has added extra viral and biologics capacity at its California plant in a $12m project that allows it to take projects from the lab to commercial scale.</itunes:summary>
      <content:encoded>
        <![CDATA[SAFC Pharma has added extra viral and biologics capacity at its California plant in a $12m project that allows it to take projects from the lab to commercial scale.]]>
      </content:encoded>
      <itunes:duration>374</itunes:duration>
      <guid isPermaLink="false"><![CDATA[90b67658-e1f8-11ea-b562-5fc64923b45f]]></guid>
      <enclosure url="https://traffic.megaphone.fm/WRBM6916627779.mp3" length="0" type="audio/mpeg"/>
    </item>
    <item>
      <title>BIO 2009: snapshot of an evolving biotech industry</title>
      <description>in-Pharmatechnologist's Nick Taylor looks back on BIO 2009, an event at which uncertainty about the development of the biotechnology industry’s future shape dominated proceedings.</description>
      <pubDate>Thu, 21 May 2009 23:00:00 -0000</pubDate>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:author>William Reed Ltd</itunes:author>
      <itunes:subtitle/>
      <itunes:summary>in-Pharmatechnologist's Nick Taylor looks back on BIO 2009, an event at which uncertainty about the development of the biotechnology industry’s future shape dominated proceedings.</itunes:summary>
      <content:encoded>
        <![CDATA[in-Pharmatechnologist's Nick Taylor looks back on BIO 2009, an event at which uncertainty about the development of the biotechnology industry’s future shape dominated proceedings.]]>
      </content:encoded>
      <itunes:duration>119</itunes:duration>
      <guid isPermaLink="false"><![CDATA[ab70a2b6-e1f8-11ea-9368-bbf2cc015769]]></guid>
      <enclosure url="https://traffic.megaphone.fm/WRBM9602414851.mp3" length="0" type="audio/mpeg"/>
    </item>
  </channel>
</rss>
